ATEC Universal Spacer System

K180480 · Alphatec Spine, Inc. · PHM · May 31, 2018 · Orthopedic

Device Facts

• Record ID: K180480
• Device Name: ATEC Universal Spacer System
• Applicant: Alphatec Spine, Inc.
• Product Code: PHM · Orthopedic
• Decision Date: May 31, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The ATEC Universal Spacer System is indicated for spinal fusion procedures in skeletally mature patients at one or two contiguous levels in the thoracolumbar spine. Thoracic: T1-T2 to T11-T12, or at the thoracolumbar junction (T12-L1), following discectomy for the treatment of a symptomatic degeneration disc disease (DDD), including thoracic disc herniation (myelopathy with or without axial pain). The lateral approach is limited to levels T5-6 to T11-T12. Lumbar: L1-L2 to L5-S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies The ATEC Universal Spacer System is intended for use on patients who have had at least six months of non-operative treatment. It is intended for use with allograft (e.g., Allogenic bone graft composed of cancellous and/or corticocancellous bone graft) and supplemental fixation systems that are cleared by FDA for use in the thoracic and lumbar spine.

Device Story

Intervertebral body fusion system; includes Battalion Universal Spacer System and Porous Ti Spacer System. Implants feature various geometries (length, width, height, lordosis) to match patient anatomy; surface teeth provide fixation to resist migration/expulsion. Used in thoracolumbar spinal fusion procedures; implanted by surgeons. Requires use with allograft bone graft and supplemental fixation systems. Benefits patients by stabilizing spinal segments and promoting fusion in DDD cases.

Clinical Evidence

No clinical data. Substantial equivalence is supported by bench testing only, including static and dynamic compression, static and dynamic compression shear, gravimetric/particulate analysis, push-out, subsidence, and bacterial endotoxin testing.

Technological Characteristics

Materials: PEEK Optima LT1 (ASTM F2026), Tantalum (ASTM F560), Ti-6Al-4V ELI (ASTM F136), Commercially Pure Titanium (ASTM F67), Titanium coating (ASTM F1580). Porous Ti implants feature layered porous geometry. Provided sterile. Mechanical fixation via surface teeth.

Indications for Use

Indicated for skeletally mature patients requiring spinal fusion at one or two contiguous levels in the thoracolumbar spine (T1-L1 or L1-S1). Targets symptomatic degenerative disc disease (DDD), including thoracic disc herniation and lumbar DDD with up to Grade I spondylolisthesis or retrolisthesis. Requires at least six months of failed non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Battalion Universal Spacer System (K160958)
• Novel Spinal Spacer System (K080699)
• NuVasive® TLX Interbody System (K171633)

Reference Devices

• Forticore System (K161485)
• Arthrex BioSync® Bone Wedge (K151256)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

May 31, 2018

Alphatec Spine, Inc Jeremy Markovich Senior Manager, Regulatory and Clinical Affairs 5818 El Camino Real Carlsbad, California 92008

Re: K180480

Trade/Device Name: ATEC Universal Spacer System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX, PHM Dated: May 3, 2018 Received: May 4, 2018

Dear Mr. Markovich:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);

{1}------------------------------------------------

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

# Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K180480

Device Name ATEC Universal Spacer System

### Indications for Use (Describe)

The ATEC Universal Spacer System is indicated for spinal fusion procedures in skeletally mature patients at one or two contiguous levels in the thoracolumbar spine.

Thoracic: T1-T2 to T11-T12, or at the thoracolumbar junction (T12-L1), following discectomy for the treatment of a symptomatic degeneration disc disease (DDD), including thoracic disc herniation (myelopathy with or without axial pain). The lateral approach is limited to levels T5-6 to T11-T12.

Lumbar: L1-L2 to L5-S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies

The ATEC Universal Spacer System is intended for use on patients who have had at least six months of non-operative treatment. It is intended for use with allograft (e.g., Allogenic bone graft composed of cancellous and/or corticocancellous bone graft) and supplemental fixation systems that are cleared by FDA for use in the thoracic and lumbar spine.

| Type of Use (Select one or both, as applicable) |
|----------------------------------------------------------------------------------------------|
| <span style="font-family: Arial;"> Prescription Use (Part 21 CFR 801 Subpart D) </span> |
| <span style="font-family: Arial;"> Over-The-Counter Use (21 CFR 801 Subpart C) </span> |

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for ATEC. The logo features a green square with a stylized white "a" inside of it. To the right of the square is the word "tec" in white, lowercase letters. The background of the logo is a dark blue color.

### 510(k) Summary

This 510(k) summary of safety and effectiveness is being submitted in accordance with the requirements of 21 CFR 807.92. The assigned 510(k) number is K180480.

| I. | SUBMITTER: | Alphatec Spine, Inc.<br>5818 El Camino Real<br>Carlsbad, CA 92008<br>Phone: [phone]<br>Fax: [phone] |
|----|------------------------|-------------------------------------------------------------------------------------------------------------------|
| | Contact Person: | Jeremy Markovich<br>Senior Manager, Regulatory and Clinical Affairs<br>Contact Phone: [phone] |
| | Date Summary Prepared: | February 22, 2018 |

#### II. DEVICE

| Name of Device: | ATEC Universal Spacer System |
|-----------------------|--------------------------------------------------------|
| Common or Usual Name: | Interbody fusion device |
| Classification Name: | Intervertebral body fusion device<br>(21 CFR 888.3080) |
| Regulatory Class: | Class II |
| Product Code: | PHM, MAX |

#### III. LEGALLY MARKETED PREDICATE AND REFERENCE DEVICES

| 510(k) | Product Code | Trade Name | Manufacturer |
|------------------------------|---------------|-----------------------------------|----------------|
| Primary Predicate Device | | | |
| K160958 | PHM, MAX | Battalion Universal Spacer System | Alphatec Spine |
| Additional Predicate Devices | | | |
| K080699 | MQP, MAX | Novel Spinal Spacer System | Alphatec Spine |
| K171633 | PHM, MAX | NuVasive® TLX Interbody System | NuVasive, Inc. |
| Reference Devices | | | |
| K161485 | MAX, ODP | Forticore System | Nanovis, LLC. |
| K151256 | PLF, HRS, HWC | Arthrex BioSync® Bone Wedge | Arthrex, Inc. |

#### IV. DEVICE DESCRIPTION

ATEC Universal Spacer System includes the Battalion Universal Spacer System and Porous Ti Spacer System.

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for Atec. The logo features a green square with a stylized white "a" inside it. To the right of the square is the word "tec" in white font, with a small "TM" symbol in the upper right corner. The background of the logo is a dark blue color.

The Battalion Universal Spacer System is an intervertebral body fusion system. The implants consist of various lengths, widths, heights and degrees of lordosis to accommodate individual patient anatomy. These implants come in three material varieties: polyetheretherketone with tantalum markers, commercially pure titanium coated polyetheretherketone with tantalum markers, and titanium alloy (Ti-6Al-4V ELI). The device includes rows of teeth on the surface of each end of the device which serve to grip the adjacent vertebrae to resist migration and expulsion of the device.

The Porous Ti Spacer System is an intervertebral body fusion system. The implants consist of various lengths, widths, heights and degrees of lordosis to accommodate individual patient anatomy. These implants are made of a commercially pure porous titanium (PTi). The device includes rows of teeth on the surface of each end of the device which serve to grip the adjacent vertebrae to resist migration and expulsion of the device. Additionally, the PTi implant is offered with a microstructure due to the layering of material that forms the porous geometry. This porous geometry extends to the superior and inferior surfaces of the device for implant fixation.

All materials are of surgical grade; polyetheretherketone (PEEK Optima LT1) conforms to ASTM F2026, tantalum conforms to ASTM F560, titanium coating conforms to ASTM F1580, the titanium alloy (Ti-6Al-4V ELI) conforms to ASTM F136, and the commercially pure titanium conforms to ASTM F67. All implants will be provided sterile.

#### V. INDICATIONS FOR USE

The ATEC Universal Spacer System is indicated for spinal fusion procedures in skeletally mature patients at one or two contiguous levels in the thoracolumbar spine.

Thoracic: T1-T2 to T11-T12, or at the thoracolumbar junction (T12-L1), following discectomy for the treatment of a symptomatic degeneration disc disease (DDD), including thoracic disc herniation (myelopathy and/or radiculopathy with or without axial pain). The lateral approach is limited to levels T5-6 to T11-T12.

Lumbar: L1-L2 to L5-S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies

The ATEC Universal Spacer System is intended for use on patients who have had at least six months of non-operative treatment. It is intended for use with allograft (e.g., Allogenic bone graft composed of cancellous and/or corticocancellous bone graft) and supplemental fixation systems that are cleared by FDA for use in the thoracic and lumbar spine.

#### TECHNOLOGICAL COMPARISON TO PREDICATES VI.

The technological design features of the subject implants were compared to the predicates in intended use, indications for use, design, function and technology and it was demonstrated that they are substantially equivalent.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for a company called "atec". The logo features a green square with a stylized "a" inside of it, followed by the text "tec" in a white, sans-serif font. The background of the logo is a dark blue color.

#### PERFORMANCE DATA VII.

The following non-clinical tests support the substantial equivalence determination as discussed in Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.

Performance data and engineering analysis demonstrate that the subject ATEC Universal Spacer System is substantially equivalent to the predicates. Testing and analysis include the following:

- Static Compression (per ASTM F2077) ●
- Dynamic Compression (per ASTM F2077) ●
- Static Compression Shear (per ASTM F2077) ●
- Dynamic Compression Shear (per ASTM F2077)
- . Gravimetric and Particulate analysis (ASTM F1714 and F1877)
- Push-out (per ASTM F04-25-02-02 Draft)
- . Subsidence (per ASTM F2267)
- Bacterial endotoxin testing (BET) per ANSI/AAMI ST72:2011/(R)2016 ●

### Clinical Information

Not applicable; determination of substantial equivalence is not based on an assessment of clinical performance data.

# VIII. CONCLUSION

Based upon the information provided in this 510(k) submission, it has been determined that the subject devices are substantially equivalent to legally marketed devices in regards to indications for use, intended use, design, technology, and performance.